Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: OTCMKTS:PLCSD
- CUSIP: N/A
- Web: ir.viveve.com/profile
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -220.16%
- Return on Equity: -220.38%
- Return on Assets: -98.50%
Frequently Asked Questions for Viveve Medical (OTCMKTS:PLCSD)
What is Viveve Medical's stock symbol?
Viveve Medical trades on the OTCMKTS under the ticker symbol "PLCSD."
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX) and ABAXIS (ABAX).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- James G. Atkinson, Chief Business Officer and President
- Patricia K. Scheller, Chief Executive Officer, Director
- Scott C. Durbin, Chief Financial Officer
- Alan Curtis, Vice President - Regulatory, Clinical and Quality
- Steve Lopez, Director - Operations
- Lori H. Bush, Director
- Debora A. Jorn, Director
- Arlene M. Morris, Director
- Jon M. Plexico, Director
- Daniel S. Janney, Independent Director
How do I buy Viveve Medical stock?
Shares of Viveve Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
MarketBeat Community Rating for Viveve Medical (OTCMKTS PLCSD)MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Viveve Medical stock can currently be purchased for approximately $0.81.
Consensus Ratings for Viveve Medical (OTCMKTS:PLCSD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Viveve Medical (OTCMKTS:PLCSD)
(Data available from 6/25/2015 forward)
|6/21/2016||Maxim Group||Lower Price Target||Buy||$16.00 -> $11.00|
Earnings History for Viveve Medical (OTCMKTS:PLCSD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Viveve Medical (OTCMKTS:PLCSD)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Viveve Medical (OTCMKTS:PLCSD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Viveve Medical (OTCMKTS:PLCSD)Insider Trades by Quarter for Viveve Medical (OTCMKTS:PLCSD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/23/2014||5Am Partners Ii, Llc||Major Shareholder||Buy||5,215,664||$0.53||$2,764,301.92|| |
|9/23/2014||Daniel Janney||Director||Buy||1,895,788||$0.53||$1,004,767.64|| |
Headline Trends for Viveve Medical (OTCMKTS:PLCSD)
Latest Headlines for Viveve Medical (OTCMKTS:PLCSD)
No headlines for this company have been tracked by MarketBeat.com
Viveve Medical (PLCSD) Chart for Sunday, June, 25, 2017